User:Mr. Ibrahem/Cabozantinib

Cabozantinib, sold under the brand names Cometriq and Cabometyx among others, is a medication used to treat medullary thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma. It is used in advanced disease or cases which have failed other treatments. It is taken by mouth.

Common side effects include diarrhea, tiredness, high blood pressure, nausea, and weight loss. Other side effects may include bleeding, fistula, blood clots, liver problems, and reversible posterior leukoencephalopathy syndrome. Use in pregnancy may harm the baby. It is a tyrosine kinase inhibitor of MET, VEGFR, and AXL.

Cabozantinib was approved for medical use in the United States in 2012 and Europe in 2014. In the United Kingdom a dose of 60 mg a day for a month costs about £5,150 as of 2021. This amount in the United States costs about 22,600 USD.